Study guide

3.3 Clinical Immunology & Hypersensitivity Reactions

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

3.3 Clinical Immunology & Hypersensitivity Reactions

Key Takeaways Explain This Topic AI

CD4+ T helper subsets are governed by specific transcription factors and signature cytokine profiles: Th1 (T-bet; IFN-γ), Th2 (GATA3; IL-4, IL-5, IL-13), Th17 (RORγt; IL-17, IL-22), and Treg (FOXP3; IL-10, TGF-β).

Hereditary angioedema (HAE) is caused by C1-esterase inhibitor deficiency, leading to uninhibited plasma kallikrein activation and excessive bradykinin generation; C4 is persistently low, and attacks do not respond to adrenaline, antihistamines, or corticosteroids.

Terminal complement pathway deficiencies (C5–C9) and treatment with eculizumab confer extreme susceptibility (> 1,000-fold) to recurrent, invasive meningococcal and gonococcal (Neisseria) infections.

Gell & Coombs Type II hypersensitivity involves antibodies against cell-surface or tissue-fixed antigens (e.g., Goodpasture's, ITP, AIHA), whereas Type III involves vascular deposition of soluble circulating immune complexes (e.g., SLE, post-streptococcal GN, serum sickness).

Chronic granulomatous disease (CGD) results from inherited mutations in the phagocyte NADPH oxidase complex (most commonly X-linked CYBB/gp91phox), preventing the respiratory burst; patients are uniquely susceptible to catalase-positive pathogens and are diagnosed via absent dihydrorhodamine-123 (DHR) oxidation.

Last updated: September 2026

Clinical immunology for MRCP(UK) Part 1 integrates lymphocyte differentiation, complement cascades, hypersensitivity reactions, and primary immunodeficiencies.

  • 1. Cellular Immunology & Immunogenetics
  • CD4+ T Helper Lineages & Cytotoxic T Cells

Naive CD4+ T cells differentiate into effector lineages guided by cytokines:

  • Subset Inducing Cytokines Master Regulator Signature Cytokines Target Organisms Clinical Pathology
  • Th1 IL-12, IFN-γ T-bet IFN-γ, IL-2 Intracellular pathogens Mycobacterial susceptibility
  • Th2 IL-4 GATA3 IL-4, IL-5, IL-13 Helminths, allergens Atopic asthma, allergic eczema
  • Th17 IL-6, IL-23 RORγt IL-17, IL-22 Fungi, extracellular bacteria Job (Hyper-IgE) syndrome (STAT3 defect)
  • Treg TGF-β, IL-2 FOXP3 IL-10, TGF-β Self-tolerance IPEX syndrome (FOXP3 defect)

CD8+ Cytotoxic T cells recognise 8–10 amino acid peptides on MHC Class I, inducing apoptosis via perforin pores, granzyme B (procaspase-3 activation), and FasL binding to target Fas (CD95).

B-Cell Maturation & Germinal Centres

Protein antigens require CD4+ T-cell help: B-cell CD40 binds CD40L (CD154) on follicular helper T cells. In germinal follicles, Activation-Induced Cytidine Deaminase (AID) drives somatic hypermutation (affinity maturation) and class switch recombination (exchanging Cμ for IgG, IgA, or IgE).

MHC Class I vs. II & HLA Disease Associations

MHC Class I (HLA-A, B, C): On all nucleated cells. Heavy α chain with β₂-microglobulin. Presents endogenous peptides loaded via TAP to CD8+ T cells .

MHC Class II (HLA-DP, DQ, DR): On APCs. α/β heterodimer presenting exogenous peptides (exchanged from CLIP by HLA-DM ) to CD4+ T cells .

  • HLA Allele Disease Associations
  • HLA-B27 Ankylosing spondylitis (RR > 90), Reactive, Psoriatic, Enteropathic arthritis
  • HLA-DR3 / HLA-DR4 Type 1 diabetes (DR3/DR4 heterozygotes highest risk); SLE (DR3); Addison's
  • HLA-DR2 Multiple sclerosis, Goodpasture's disease
  • HLA-DQ2 / HLA-DQ8 Coeliac disease (> 95% HLA-DQ2)
  • HLA-B51 Behçet's disease
  • HLA-B*5701 Abacavir hypersensitivity (mandatory pre-treatment screening)
  • HLA-B*1502 Carbamazepine Stevens-Johnson syndrome in East Asians
  • 2. Complement Cascade & Deficiency Syndromes
  • Pathways & Membrane Attack Complex (MAC)

Classical: Antigen-bound IgM or IgG (IgG1, IgG3) binds C1q , cleaving C4 and C2 into C4b2a (C3 convertase) . IgG4 does not fix complement.

Lectin: Mannose-binding lectin activates MASP-1/2 to generate C4b2a .

Alternative: Spontaneous C3 hydrolysis and Factor B/D generate C3bBb on microbial surfaces.

Terminal Pathway: C3 convertases cleave C3 into C3a (anaphylatoxin) and C3b (opsonin). Addition of C3b produces C5 convertase, generating C5a (potent chemoattractant) and C5b . C5b recruits C6–C9 to assemble the MAC (C5b-9) , creating lytic transmembrane pores.

Complement Deficiency States

C1, C4, C2 Deficiencies: Impaired immune-complex clearance; >90% of C1q-deficient individuals develop severe SLE .

C3 Deficiency: Severe recurrent pyogenic encapsulated infections ( S. pneumoniae , H. influenzae ).

Terminal Deficiencies (C5–C9): Inability to form MAC. Extreme susceptibility to recurrent, invasive Neisseria infections (meningococcal meningitis). Eculizumab (anti-C5 mAb) produces identical vulnerability.

C1-INH Deficiency (Hereditary Angioedema, HAE): Autosomal dominant loss of C1-INH causes unchecked plasma kallikrein activation, generating excessive bradykinin (not histamine). Causes recurrent non-pruritic, non-pitting oedema (face, bowel wall colic, laryngeal obstruction); no urticaria . Serum C4 is persistently low ; C1q is normal. Adrenaline is ineffective; treat with C1-INH concentrate , icatibant , or ecallantide .

Paroxysmal Nocturnal Haemoglobinuria (PNH): Somatic PIGA mutation causes absence of GPI-anchored CD55 (DAF) and CD59 (protectin) , causing complement-mediated haemolysis and thrombosis. Diagnosed by flow cytometry (FLAER).

3. Gell & Coombs Classification of Hypersensitivity

Type Immune Mechanism Mediators Clinical Examples

Type I Immediate / IgE-Mediated: Allergen cross-links specific IgE on mast cells; degranulation Histamine, tryptase, leukotrienes (LTC₄, LTD₄) Anaphylaxis, asthma, urticaria. Measured by mast cell tryptase (peaks 1–2 h)

Type II Antibody Cytotoxic: IgG/IgM against fixed tissue/cell antigens; complement or ADCC IgG, IgM, complement (MAC), NK cells Goodpasture's (anti-GBM), AIHA, ITP, Myasthenia gravis, Graves'

Type III Immune-Complex: Soluble antigen-antibody complexes deposit in microvasculature, activating complement Immune complexes, C3a/C5a, neutrophils SLE (lupus nephritis), Post-streptococcal GN, Serum sickness (fever, rash, low C3/C4)

Type IV Delayed / Cell-Mediated: Sensitised T cells recruit macrophages or mediate direct lysis CD4+ (Th1/17), CD8+ T cells, IFN-γ Mantoux test , contact dermatitis (nickel), SJS / TEN, Coeliac disease

4. Primary Immunodeficiency Disorders

Severe Combined Immunodeficiency (SCID): Profound T/B cell deficiency causing failure to thrive, candidiasis, diarrhoea, and opportunistic infections ( P. jirovecii ). X-linked (~50%) IL2RG mutation (common γc; T⁻ B⁺ NK⁻); autosomal recessive ADA deficiency (T⁻ B⁻ NK⁻). Treatment: stem cell transplantation.

X-Linked Agammaglobulinaemia (Bruton's XLA): BTK mutation halts B-cell development. Absent circulating B cells ( CD19+, CD20+ < 1% ) and marked hypogammaglobulinaemia. Presents after 6 months (waning maternal IgG) with pyogenic infections. Hallmark: absent tonsils and lymph nodes . Treatment: lifelong IVIG/SCIG.

Common Variable Immunodeficiency (CVID): Most common symptomatic primary antibody deficiency in adults (20–40 years). Defective plasma cell differentiation causes low IgG plus low IgA/IgM and impaired vaccine responses despite normal B-cell counts. Sinopulmonary infections, Giardia , granulomas, cytopenias (ITP/AIHA), and lymphoma risk. Treatment: lifelong IVIG/SCIG.

Selective IgA Deficiency: Most common primary immunodeficiency (~1 in 600). Undetectable IgA (< 0.07 g/L) with normal IgG/IgM. Causes mucosal infections, atopy, and coeliac disease. High risk of severe anaphylaxis to IgA-containing blood products (anti-IgA antibodies; requires washed RBCs).

Hyper-IgM Syndrome: X-linked CD40LG (CD154) mutation prevents class switching. Normal/elevated IgM with severe IgG, IgA, and IgE deficiency. Recurrent pyogenic and opportunistic infections ( Pneumocystis , Cryptosporidium ).

Chronic Granulomatous Disease (CGD): Phagocyte NADPH oxidase defect (most commonly X-linked CYBB / gp91phox ) eliminates the respiratory burst. Phagocytes ingest but cannot kill catalase-positive organisms ( S. aureus , Burkholderia , Serratia , Nocardia , Aspergillus ). Diagnosed by absent Dihydrorhodamine-123 (DHR) oxidation on flow cytometry. Treatment: co-trimoxazole, itraconazole, IFN-γ, HSCT.